A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

October 31, 2019
https://clinicaltrials.gov/ct2/show/NCT03711032
Cancer - Bladder
Principal Investigator: James O Peabody, MD

Pembrolizumab

BCG

Non-muscle Invasive Bladder

KEYNOTE-676

MK-3475-676

Bladded

Open